Journal of Medicinal Chemistry
Article
Verdoliva, A.; Bottazzi, B.; Mantovani, A.; Salvatori, G.; Day, A. J. The
angiogenic inhibitor long pentraxin PTX3 forms an asymmetric
octamer with two binding sites for FGF2. J. Biol. Chem. 2010, 285,
17681−17692.
REFERENCES
■
(1) Bikfalvi, A.; Klein, S.; Pintucci, G.; Rifkin, D. B. Biological roles of
fibroblast growth factor-2. Endocr. Rev. 1997, 18, 26−45.
(2) Schlessinger, J.; Plotnikov, A. N.; Ibrahimi, O. A.; Eliseenkova, A.
V.; Yeh, B. K.; Yayon, A.; Linhardt, R. J.; Mohammadi, M. Crystal
structure of a ternary FGF-FGFR-Heparin complex reveals a dual role
for heparin in FGFR binding and dimerization. Mol. Cell 2000, 6,
743−750.
(3) Beenken, A.; Mohammadi, M. The FGF family: biology,
pathophysiology and therapy. Nat. Rev. Drug Discovery 2009, 8,
235−253.
(4) (a) Folkman, J.; Klagsbrun, M. Angiogenic factors. Science 1987,
235, 442−447. (b) Presta, M.; Dell’Era, P.; Mitola, S.; Moroni, E.;
Ronca, R.; Rusnati, M. Fibroblast growth factor/fibroblast growth
factor receptor system in angiogenesis. Cytokine Growth Factor Rev.
2005, 16, 159−178. (c) Brooks, A. N.; Kilgour, E.; Smith, P. D.
Molecular pathways: fibroblast growth factor signaling: a new
therapeutic opportunity in cancer. Clin. Cancer Res. 2012, 18, 1855−
1862.
(12) (a) Giacomini, A.; Matarazzo, S.; Pagano, K.; Ragona, L.;
Rezzola, S.; Corsini, M.; Di Salle, E.; Presta, M.; Ronca, R. A long
pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven
steroid hormone-regulated cancers. Oncotarget 2015, 6, 13790−13802.
(b) Leali, D.; Bianchi, R.; Bugatti, A.; Nicoli, S.; Mitola, S.; Ragona, L.;
Tomaselli, S.; Gallo, G.; Catello, S.; Rivieccio, V.; Zetta, L.; Presta, M.
Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-
derived anti-angiogenic pentapeptide. J. Cell. Mol. Med. 2010, 14,
2109−2121.
(13) Developmental Therapeutics Program, NCI/NIH. https://dtp.
(14) Ronca, R.; Giacomini, A.; Di Salle, E.; Coltrini, D.; Pagano, K.;
Ragona, L.; Matarazzo, S.; Rezzola, S.; Maiolo, D.; Torrella, R.;
Moroni, E.; Mazzieri, R.; Escobar, G.; Mor, M.; Colombo, G.; Presta,
M. Long-pentraxin 3 derivative as a small-molecule FGF trap for
cancer therapy. Cancer Cell 2015, 28, 225−239.
(15) On the basis of the NCI structure, only one option is available
for the steroidal skeleton: a pregnane-type, with no ambiguities
regarding the ring junction owing to the Δ5,6-unsaturation.
(16) Given the lower priority of the entering group, the attack on the
si face leads to the 20 R diastereoisomer. Typical nucleophilic reducing
agents (NaBH4, LiAlH4, borane−dimethylsulfide, etc.) provide the
20R product in high epimeric purity. Midland, M. M.; Kwon, Y. C.
Stereochemistry of hydroboration of α-chiral olefins and reduction of
α-chiralketones. An unusual anti-Cram selectivity with dialkylboranes.
J. Am. Chem. Soc. 1983, 105, 3725−3727.
(5) Morrison, R. S.; Shi, E.; Kan, M.; Yamaguchi, F.; McKeehan, W.;
Rudnicka-Nawrot, M.; Palczewski, K. Inositol hexakisphosphate
(InsP6): an antagonist of fibroblast growth factor receptor binding
and activity. In Vitro Cell. Dev. Biol.: Anim. 1994, 30A, 783−789.
(6) Hu, M.−M.; Hu, Y.; Gao, G.−K.; Han, Y.; Shi, G.−L.; Li, B.−I.
Basic fibroblast growth factor shows prognostic impact on survival in
operable non-small cell lung cancer patients. Thorac. Cancer 2015, 6,
450−457.
(7) Weiss, J.; Sos, M. L.; Seidel, D.; Peifer, M.; Zander, T.;
Hueckmann, J. M.; Ullrich, R. T.; Menon, R.; Maier, S.; Soltermann,
A.; Moch, H.; Wagener, P.; Fischer, F.; Heynck, S.; Koker, M.;
(17) In no instances could we observe products arising from the
enolization at C17 (thermodynamic enolate) despite the relatively
high temperature needed for the enolization. When kept at lower
temperature for longer times, the yield was consistently poor.
(18) Ikeda, M.; Matsumura, H.; Sawada, N.; Hashimoto, K.; Tanaka,
T.; Noguchi, T.; Hayashi, M. Synthesis and biological evaluations of C-
23-modified 26,26,26,27,27,27-F6-vitamin D3 analogues. Bioorg. Med.
Chem. 2000, 8, 1809−1817.
Schottle, J.; Leenders, F.; Gabler, F.; Dabow, I.; Querings, S.;
̈
Heukamp, L. C.; Balke-Want, H.; Ansen
́
, S.; Rauh, D.; Baessmann, I.;
Altmuller, J.; Wainer, Z.; Conron, M.; Wright, G.; Russell, P.;
̈
Solomon, B.; Brambilla, E.; Brambilla, C.; Lorimier, P.; Sollberg, S.;
Brustugun, O. T.; Engel-Riedel, W.; Ludwig, C.; Petersen, I.; Sanger,
̈
J.; Clement, J.; Groen, H.; Timens, W.; Sietsma, H.; Thunnissen, E.;
Smit, E.; Heideman, D.; Cappuzzo, F.; Ligorio, C.; Damiani, S.; Hallek,
M.; Beroukhim, R.; Pao, W.; Klebl, B.; Baumann, M.; Buettner, R.;
(19) Fukase, H.; Horii, S. Synthesis of a branched-chain inosose
derivative, a versatile synthon of N-substituted valiolamine derivatives
from D-glucose. J. Org. Chem. 1992, 57, 3642−3650.
Ernestus, K.; Stoelben, E.; Wolf, J.; Nurnberg, P.; Perner, S.; Thomas,
̈
R. K. Frequent and focal FGFR1 amplification associates with
therapeutically tractable FGFR1 dependency in squamous cell lung
cancer. Sci. Transl. Med. 2010, 2, 62ra93.
(20) We excluded different steroidal skeletons, as the 1H NMR
spectra were extremely similar and the ESI-MS spectra matched
perfectly.
(21) Evans, D. A.; Chapman, K. T.; Carreira, E. M. Direct reduction
of β-hydroxy ketones employing tetramethylammonium triacetoxybor-
ohydride. J. Am. Chem. Soc. 1988, 110, 3560−3578.
(22) Relevant NMR spectra are reported in the Supporting
(23) Karplus, M. Vicinal proton coupling in nuclear magnetic
resonance. J. Am. Chem. Soc. 1963, 85, 2870−2871.
(24) Maestro, version 9.7; Schrodinger LLC: New York, 2009.
(25) Bachers, G. E.; Schaefer, T. Applications of the intramolecular
nuclear Overhauser effect in structural organic chemistry. Chem. Rev.
1971, 71, 617−626.
(26) Nicolaou, K. C.; Li, Y.; Sugita, K.; Monenschein, H.; Guntupalli,
P.; Mitchell, H. J.; Fylaktakidou, K. C.; Vourloumis, D.; Giannakakou,
P.; O’Brate, A. Total synthesis of apoptolidin: completion of the
synthesis and analogue synthesis and evaluation. J. Am. Chem. Soc.
2003, 125, 15443−15454.
(27) (a) Eckert, H.; Forster, B. Triphosgene, a crystalline phosgene
substitute. Angew. Chem., Int. Ed. Engl. 1987, 26, 894−895.
(b) Fujiwara, K.; Aki, Y.-I.; Yamamoto, F.; Kawamura, M.;
Kobayashi, M.; Okano, A.; Awakura, D.; Shiga, S.; Murai, A.; Kawai,
H.; Suzuki, T. Synthesis of the C8-C20 and C21-C30 segments of
pectenotoxin 2. Tetrahedron Lett. 2007, 48, 4523−4527.
(28) Euhus, D. M.; Hudd, C.; La Regina, M. C.; Johnson, F. E.
Tumor measurement in the nude mouse. J. Surg. Oncol. 1986, 31,
229−234.
(8) (a) Burbridge, M. F.; Bossard, C. J.; Saunier, C.; Fejes, I.; Bruno,
A.; Leo
Jacquet-Bescond, A.; Comoglio, P. M.; Lockhart, B. P.; Boutin, J. A.;
Cordi, A.; Ortuno, J. C.; Pierre, A.; Hickman, J. A.; Cruzalegui, F. H.;
́
nce, S.; Ferry, G.; Da Violante, G.; Bouzom, F.; Cattan, V.;
́
Depil, S. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR
with strong preclinical activity alone and in association with
bevacizumab. Mol. Cancer Ther. 2013, 12, 1749−1762. (b) Ho, H.
K.; Yeo, A. H.; Kang, T. S.; Chua, B. T. Current strategies for
inhibiting FGFR activities in clinical applications: opportunities,
challenges and toxicological considerations. Drug Discovery Today
2014, 19, 51−62. (c) Ronca, R.; Benzoni, P.; Leali, D.; Urbinati, C.;
Belleri, M.; Corsini, M.; Alessi, P.; Coltrini, D.; Calza, S.; Presta, M.;
Dell’Era, P. Antiangiogenic activity of a neutralizing human single-
chain antibody fragment against fibroblast growth factor receptor 1.
Mol. Cancer Ther. 2010, 9, 3244−3253.
(9) Dieci, M. V.; Arnedos, M.; Andre, F.; Soria, J. C. Fibroblast
growth factor receptor inhibitors as a cancer treatment: from a biologic
rationale to medical perspectives. Cancer Discovery 2013, 3, 264−279.
(10) (a) Harding, T. C.; Long, L.; Palencia, S.; Zhang, H.; Sadra, A.;
Hestir, K.; Patil, N.; Levin, A.; Hsu, A. W.; Charych, D.; Brennan, T.;
Zanghi, J.; Halenbeck, R.; Marshall, S. A.; Qin, M.; Doberstein, S. K.;
Hollenbaugh, D. W.; Kavanaugh, W. M.; Williams, L. T.; Baker, K. P.
Blockade of nonhormonal fibroblast growth factors by FP-1039
inhibits growth of multiple types of cancer. Sci. Transl. Med. 2013, 5,
178ra39.
(11) Inforzato, A.; Baldock, C.; Jowitt, T. A.; Holmes, D. F.;
Lindstedt, R.; Marcellini, M.; Rivieccio, V.; Briggs, D. C.; Kadler, K. E.;
L
J. Med. Chem. XXXX, XXX, XXX−XXX